Non-squamous cell lung cancer
Showing 1 - 25 of >10,000
Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)
Not yet recruiting
- Non Squamous Non Small Cell Lung Cancer
- EGFR Positive Non-small Cell Lung Cancer
- Toripalimab plus Chemotherapy
- (no location specified)
Jul 28, 2023
Advanced Squamous Non Small Cell Lung Cancer Trial (AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel)
Not yet recruiting
- Advanced Squamous Non Small Cell Lung Cancer
- AK112, Carboplatin, Paxlitaxel
- Tislelizumab, Carboplatin, Paxlitaxel
- (no location specified)
Apr 21, 2023
Advanced Squamous Non-Small-Cell Lung Cancer Trial (Trilaciclib, Carboplatin, Paclitaxel)
Not yet recruiting
- Advanced Squamous Non-Small-Cell Lung Cancer
- Trilaciclib
- +3 more
- (no location specified)
Jun 11, 2023
NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Cadonilimab
- +2 more
-
Wuhan, Hubei, ChinaQian Chu
Aug 18, 2023
NSCLC Trial (Ivonescimab Injection, Pembrolizumab Injection)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Ivonescimab Injection
- Pembrolizumab Injection
- (no location specified)
Jun 9, 2023
Advanced or Metastatic Squamous NSCLC Trial in Sydney (HMBD-001, Docetaxel, Cetuximab)
Not yet recruiting
- Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
- HMBD-001
- +2 more
-
Sydney, New South Wales, AustraliaGenesisCare North Shore
Jun 20, 2023
NSCLC Trial in Wuhan (Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel)
Recruiting
- Non-small Cell Lung Cancer
- Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel
-
Wuhan, Hubei, ChinaUnion hospital
Feb 20, 2023
NSCLC Trial in Chongqing (procedure, drug, radiation)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- bronchial artery interventional therapy
- +3 more
-
Chongqing, Chongqing, ChinaDaping Hospital, Third Military Medical University
May 27, 2023
NSCLC Trial in Pittsburgh (M1774, Cemiplimab)
Not yet recruiting
- Non-Small Cell Lung Cancer
-
Pittsburgh, PennsylvaniaUPMC Cancer Center
May 22, 2023
NSCLC Trial in Pittsburgh (Tiragolumab, Atezolizumab, Pemetrexed)
Not yet recruiting
- Non-small Cell Lung Cancer
- Tiragolumab
- +3 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Feb 16, 2023
PARP Inhibitor for Esophageal Squamous Cell Carcinoma Trial (Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only
Not yet recruiting
- PARP Inhibitor for Esophageal Squamous Cell Carcinoma
- Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))
- (no location specified)
Sep 24, 2023
Sinonasal Cancer, Squamous NSCLC, Lung Cancer Trial run by the National Cancer Institute (NCI) (pembrolizumab, valemetostat)
Not yet recruiting
- Sinonasal Cancer
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jun 5, 2023
Non Squamous Non Small Cell Lung Cancer Trial in Korea, Republic of (Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin)
Not yet recruiting
- Non Squamous Non Small Cell Lung Cancer
- Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin
-
Anam, Korea, Republic of
- +7 more
May 1, 2023
NSCLC, Brain Tumors Trial (bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents)
Completed
- Non-Small Cell Lung Cancer
- Brain Neoplasms
- bevacizumab
- +2 more
- (no location specified)
Dec 9, 2022
Non-squamous Non-small-cell Lung Cancer, Brain Metastases Trial in Guangzhou (Camrelizumab, Pemetrexed, Carboplatin)
Active, not recruiting
- Non-squamous Non-small-cell Lung Cancer
- Brain Metastases
- Camrelizumab
- +2 more
-
Guangzhou, Guangzhou, ChinaLi-Kun Chen
Nov 13, 2022
Non-squamous NSCLC, Epithelial Ovarian Cancer Trial (AMG 794)
Not yet recruiting
- Non-squamous Non-small Cell Lung Cancer
- Epithelial Ovarian Cancer
- AMG 794
-
Orange, CaliforniaUniversity of California at Irvine
Jan 25, 2023
Non-squamous NSCLC Trial in Guangzhou (FSRT combined with Bevacizumab)
Active, not recruiting
- Non-squamous Non-small Cell Lung Cancer
- FSRT combined with Bevacizumab
-
Guangzhou, ChinaSun Yat-sen University
Nov 25, 2022
Non-squamous Non-small-cell Lung Cancer Trial in Hangzhou (Tusamitamab ravtansine+Sintilimab+Carboplatin or
Not yet recruiting
- Non-squamous Non-small-cell Lung Cancer
- Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
- +2 more
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
May 5, 2023
Advanced Non-squamous Non-Small-Cell Lung Cancer Trial in Jinan (Sintilimab)
Recruiting
- Advanced Non-squamous Non-Small-Cell Lung Cancer
-
Jinan, Shandong, ChinaThe First Affiliated Hospital of Shandong First Medical Universi
Dec 4, 2022
Lung Cancer, Non-squamous, Non-small Cell Trial (zongertinib, pembrolizumab, cisplatin)
Not yet recruiting
- Lung Cancer, Non-squamous, Non-small Cell
- zongertinib
- +4 more
- (no location specified)
Nov 22, 2023
NSCLC Trial in Guangzhou (Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
-
Guangzhou, Guang Dong, ChinaSun Yat-sen University Cancer Center
Nov 3, 2022
Metastatic Squamous Non-Small Cell Lung Carcinoma Trial in Chicago (Cabozantinib 40 MG, Pembrolizumab 200mg)
Recruiting
- Metastatic Squamous Non-Small Cell Lung Carcinoma
- Cabozantinib 40 MG
- Pembrolizumab 200mg
-
Chicago, IllinoisUniversity of Illinois at Chicago
Jan 20, 2023
Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung
Not yet recruiting
- Advanced Non-squamous Non-small-cell Lung Cancer
- +2 more
- pembrolizumab
- +2 more
-
Beijing, Beijing, ChinaPeking University First Hospital Ethics Committee
Sep 10, 2023
Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)
Recruiting
- Non-squamous Non-small-cell Lung Cancer
- +4 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jan 8, 2023